Looking forward to our webinar with @BURSTurology tomorrow morning: Thursday 23rd October at 09.00 Register here: https://t.co/mROoucmbaT and tell your friends/colleagues See you then!

Looking forward to our webinar with @BURSTurology More details can be found on our website https://t.co/mROoucmJ0r Find your sMDT's results on our data dashboard https://t.co/SAPmpONOwN and more details in our State of the Nation Report 2025

Sign up for our webinar on 23.10.25 at 09.00 👇 https://t.co/09GaCKNa5y

📢NPCA State of the Nation Report 2025 is OUT! Report, supplementary documents & provider results: https://t.co/pEyNLw3ieR @NATCAN_news @HQIP @RCSnews @BAUSurology @BUG_UK25 @ProstateUK @NHSEngland @alison_tree @GUresearch_MCR @JKHLiu @JoannaDodkins @ArjunSNathan Pls share!

We're excited to be joining forces with @BURSTurology to bring you this webinar, as part of our QI Intervention. Hosted by our excellent clinical leads @alison_tree and Noel Clarke, and featuring our newest clinical fellow, Justin Liu, who will be presenting some case studies.

💡NPCA Clinical Lead @alison_tree will present (unpublished) key findings from the upcoming State of the Nation Report and NPCA research updates at the British Uro-oncology Group @BUG_UK25 Annual Meeting. 🗓️ Sept 13 @ 9.15 🔗  https://t.co/FV09L95YfM @NATCAN_news @ProstateUK

ICYMI Read the National Prostate Cancer Audit blog post for Clinical Audit Awareness Week #CAAW25 @HQIP "The value of audit in identifying health inequalities" https://t.co/vzUgstt95N Draws on NPCA State of the Nation report from January 2025

⚠️ICYMI our latest study investigating 👉 geographic 👉 socioeconomic 👉 demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England https://t.co/xb666q3yVR

Taken together, these findings highlight the importance of refocusing efforts on prostate cancer screening and detection policies in England and the UK. @NATCAN_news @alison_tree @JoannaDodkins @GUresearch_MCR @ProstateUK

A higher rate of metastatic prostate cancer and a lower rate of prostate cancer overall was also seen among men living in more deprived neighbourhoods, suggesting that the risk of being diagnosed with metastatic prostate cancer is also linked to their socioeconomic background.

⚠️ Another key finding of this study is that higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall which may be linked to variation in the use of PSA testing.

🚨 Regional annual rates were found to vary between 4-7/100 000 men, with the highest rates seen in Northern England; South Yorkshire and Bassetlaw; Humber, Coast and Vale; West Yorkshire and Harrogate; and the Peninsula. The lowest rates were seen in London and the South-East.

📢 Start your week with the latest National Prostate Cancer Audit study. We found that the annual rate of metastatic prostate cancer at diagnosis was more than 60% higher in some regions than in others in England. Paper link here 👉 https://t.co/dvifBybe8r

The *first* National Prostate Cancer Audit Quarterly Data Dashboard is LIVE 📊 Cohort and indicator details can be found here https://t.co/vnKibBvzt2 and the dashboard is accessible here https://t.co/58o7AQMneY Please share and tell us what you think! 📝 npca@rcseng.ac.uk

💥Read our Lancet Oncology paper 💥 https://t.co/bSIcPb3epY “NATCAN provides an opportunity to use data science to inform clinical quality improvement across a range of cancers and reduce unwarranted variation in care.” @RCSnews @LSHTM @HQIP @NHSEngland @AggarwalOnc

ICYMI last week, the NPCA's latest paper "Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England" 👉 https://t.co/pFpxV6kL7i

Congratulations Lauren!

👉 Use varied across sMDTs from 20% to 54%, with greater variation in older patients 👉 Findings highlight underuse and the need for standardised care to address disparities We hope you find this paper useful and please get in touch with any feedback npca@rcseng.ac.uk

The study explored variation in treatment intensification for mHSPC across England and found : 👉 Only 39% received intensification with lower uptake in Black and deprived populations 👉 Intensification was given to 60% of men under 75 but dropped to 17% in those over 75

📢 Read our hot off the press paper: "Are Evidence-Based Guidelines Translating into Clinical Practice? A National Population-Based Study of the Use of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in England" https://t.co/LfCo51Kru1